Clinical Trial Update: Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating anlotinib in combination with docetaxel for EGFR/ALK/ROS1 mutation-negative advanced nonsquamous non-small cell lung cancer is ongoin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib + Docetaxel

Snippet

Sponsor: First Affiliated Hospital of Guangxi Medical University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN